CoraLite® Plus 488-conjugated IGFBP6 Monoclonal antibody

IGFBP6 Monoclonal Antibody for FC (Intra)

Host / Isotype

Mouse / IgG2b

Reactivity

Human

Applications

FC (Intra)

Conjugate

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1D12B3

Cat no : CL488-67567

Synonyms

IBP 6, IBP6, IGF binding protein 6, IGFBP 6, IGFBP6

---

Validation Data Gallery

• 

  FC experiment of A431 using CL488-67567

  1X10^6 A431 cells were intracellularly stained with 0.4 ug CoraLite® Plus 488 Anti-Human IGFBP6 (CL488-67567, Clone:1D12B3) (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

---

Tested Applications

• Positive FC detected in: A431 cells

Recommended dilution

• Flow Cytometry (FC): FC : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

CL488-67567 targets IGFBP6 in FC (Intra) applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Host / Isotype: Mouse / IgG2b
• Class: Monoclonal
• Type: Antibody
• Immunogen: IGFBP6 fusion protein Ag30050
• Full Name: insulin-like growth factor binding protein 6
• Calculated Molecular Weight: 25 kDa
• Observed Molecular Weight: 30-33 kDa
• GenBank Accession Number: BC011708
• Gene Symbol: IGFBP6
• Gene ID (NCBI): 3489
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain. It modulates the activity of IGF and shows independent effects of IGF, such as growth inhibition and apoptosis. It can decrease the proliferation and survival of cancer cells such as lung cancer cells and naso-pharyngeal cancer cells. IGFBP-6 is distinctive for its 50-fold higher binding affinity for IGF-II over IGF-I and this specificity makes it an attractive potential therapeutic candidate for IGF-II-dependent pediatric malignancies such as rhabdomyosarcoma (RMS). In addition, it was found that IGFBP6 can promote the migration of RMS cells in an IGF-independent manner, and MAPK pathways were involved in this process. Further study reported that IGFBP6 is one of most highly expressed proteins in varicose vein tissues and is involved in the proliferation of vascular smooth muscle cells (VSMCs), which may provide insights into the underlying pathogenesis of varicose vein.